Syros Pharmaceuticals’ (SYRS) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note published on Wednesday morning, Marketbeat.com reports. They currently have a $1.00 target price on the stock, down from their previous target price of $6.00. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q1 2025 earnings at ($0.70) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.69) EPS.

Several other research firms have also issued reports on SYRS. StockNews.com lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and set a $5.00 price target (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. JMP Securities reduced their price target on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Syros Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Performance

NASDAQ SYRS opened at $0.26 on Wednesday. The firm has a 50-day moving average price of $1.99 and a two-hundred day moving average price of $3.75. Syros Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $8.17. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $6.96 million, a P/E ratio of -0.09 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the business posted ($1.35) EPS. Analysts anticipate that Syros Pharmaceuticals will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CEO Conley Chee purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average price of $1.51 per share, with a total value of $75,500.00. Following the completion of the purchase, the chief executive officer now owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. The trade was a 222.18 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jason Haas purchased 35,363 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $1.55 per share, with a total value of $54,812.65. Following the purchase, the chief financial officer now directly owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. The trade was a 144.03 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 130,707 shares of company stock worth $206,491 over the last quarter. Corporate insiders own 12.26% of the company’s stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several large investors have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals during the third quarter valued at $34,000. Certuity LLC bought a new position in Syros Pharmaceuticals during the second quarter worth $109,000. Acadian Asset Management LLC raised its stake in Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after buying an additional 17,416 shares during the last quarter. Opaleye Management Inc. raised its stake in Syros Pharmaceuticals by 119.1% during the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after buying an additional 428,175 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Syros Pharmaceuticals during the first quarter worth $64,000. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.